Muscle Structure Influences Utrophin Expression in mdx Mice

PLoS Genetics

Volumn 10, Issue 6, 2014, Pages

  Banks, Glen B ^a   Combs, Ariana C ^a   Odom, Guy L ^a   Bloch, Robert J ^b   Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA DYSTROBREVIN 1; ALPHA DYSTROBREVIN 2; ALPHA SARCOMERIC ACTIN; ALPHA1 SYNTROPHIN; BETA DYSTROGLYCAN; COLLAGEN; DESMIN; DYSTROBREVIN; MESSENGER RNA; NITRIC OXIDE SYNTHASE; SYNTROPHIN; UNCLASSIFIED DRUG; UTROPHIN; CALCIUM BINDING PROTEIN; DYSTROPHIN; DYSTROPHIN ASSOCIATED PROTEIN; MEMBRANE PROTEIN; MUSCLE PROTEIN; NOTEXIN; SNAKE VENOM; SYNTROPHIN ALPHA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GASTROCNEMIUS MUSCLE; GENE DELETION; GENOTYPE; HISTOPATHOLOGY; IMMUNOPATHOLOGY; MALE; MEMBRANE BIOLOGY; MEMBRANE FRAGILITY; MOLECULAR DYNAMICS; MORTALITY; MOUSE; MUSCLE CHARACTERISTICS AND FUNCTIONS; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCLE STEM CELL; MUSCLE STRUCTURE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SARCOLEMMA; SARCOMERE; STEM CELL; SURVIVAL RATE; WILD TYPE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; CALCIUM-BINDING PROTEINS; DESMIN; DYSTROPHIN; DYSTROPHIN-ASSOCIATED PROTEINS; ELAPID VENOMS; INFLAMMATION; MACROPHAGES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; SARCOLEMMA; SARCOMERES; UTROPHIN;

EID: 84903451826     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004431     Document Type: Article

References (118)

1. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, et al. (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71: 304-313.
2. Hoffman EP, Brown RH Jr, Kunkel LM, (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
3. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517.
4. Bhasin N, Law R, Liao G, Safer D, Ellmer J, et al. (2005) Molecular extensibility of mini-dystrophins and a dystrophin rod construct. J Mol Biol 352: 795-806.
5. Mirza A, Sagathevan M, Sahni N, Choi L, Menhart N, (2010) A biophysical map of the dystrophin rod. Biochim Biophys Acta 1804: 1796-1809.
6. Henderson DM, Lee A, Ervasti JM, (2010) Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation. Proc Natl Acad Sci U S A 107: 9632-9637.
7. Ervasti JM, Sonnemann KJ, (2008) Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol 265: 191-225.
8. Ervasti JM, Campbell KP, (1991) Membrane organization of the dystrophin-glycoprotein complex. Cell 66: 1121-1131.
9. Koenig M, Kunkel LM, (1990) Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J Biol Chem 265: 4560-4566.
10. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP, (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345: 315-319.
11. Ervasti JM, (2007) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta 1772: 108-117.
12. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, et al. (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456: 511-515.
13. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, et al. (1999) Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1: 215-220.
14. Brooks SV, (1998) Rapid recovery following contraction-induced injury to in situ skeletal muscles in mdx mice. J Muscle Res Cell Motil 19: 179-187.
15. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV, (2001) Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 22: 467-475.
16. Faulkner JA, Ng R, Davis CS, Li S, Chamberlain JS, (2008) Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clin Exp Pharmacol Physiol 35: 725-729.
17. Moens P, Baatsen PH, Marechal G, (1993) Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 14: 446-451.
18. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL, (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90: 3710-3714.
19. Banks GB, Chamberlain JS, (2008) The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 84: 431-453.
20. Love DR, Hill DF, Dickson G, Spurr NK, Byth BC, et al. (1989) An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339: 55-58.
21. Khurana TS, Watkins SC, Chafey P, Chelly J, Tome FM, et al. (1991) Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord 1: 185-194.
22. Pons F, Nicholson LV, Robert A, Voit T, Leger JJ, (1993) Dystrophin and dystrophin-related protein (utrophin) distribution in normal and dystrophin-deficient skeletal muscles. Neuromuscul Disord 3: 507-514.
23. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, et al. (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717-727.
24. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, et al. (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90: 729-738.
25. Chevron MP, Echenne B, Demaille J, (1994) Absence of dystrophin and utrophin in a boy with severe muscular dystrophy. N Engl J Med 331: 1162-1163.
26. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, et al. (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4: 1441-1444.
27. Karpati G, Carpenter S, Morris GE, Davies KE, Guerin C, et al. (1993) Localization and quantitation of the chromosome 6-encoded dystrophin-related protein in normal and pathological human muscle. J Neuropathol Exp Neurol 52: 119-128.
28. Mizuno Y, Nonaka I, Hirai S, Ozawa E, (1993) Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. J Neurol Sci 119: 43-52.
29. Kleopa KA, Drousiotou A, Mavrikiou E, Ormiston A, Kyriakides T, (2006) Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum Mol Genet 15: 1623-1628.
30. Vainzof M, Passos-Bueno MR, Man N, Zatz M, (1995) Absence of correlation between utrophin localization and quantity and the clinical severity in Duchenne/Becker dystrophies. Am J Med Genet 58: 305-309.
31. Taylor J, Muntoni F, Dubowitz V, Sewry CA, (1997) The abnormal expression of utrophin in Duchenne and Becker muscular dystrophy is age related. Neuropathol Appl Neurobiol 23: 399-405.
32. Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, et al. (2013) Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24: 797-806.
33. Fairclough RJ, Wood MJ, Davies KE, (2013) Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet 14: 373-378.
34. Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, et al. (2013) Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 123: 5310-5318.
35. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, et al. (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A 108: 762-767.
36. Helliwell TR, Man NT, Morris GE, Davies KE, (1992) The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromuscul Disord 2: 177-184.
37. Weir AP, Morgan JE, Davies KE, (2004) A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. Neuromuscul Disord 14: 19-23.
38. Ljubicic V, Burt M, Jasmin BJ, (2013) The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets. FASEB J 28: 548-568.
39. Marshall JL, Kwok Y, McMorran BJ, Baum LG, Crosbie-Watson RH, (2013) The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy. FEBS J 280: 4210-4229.
40. Banks GB, Combs AC, Chamberlain JR, Chamberlain JS, (2008) Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum Mol Genet 17: 3975-3986.
41. Banks GB, Judge LM, Allen JM, Chamberlain JS, (2010) The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet 6: e1000958.
42. Lazarides E, Hubbard BD, (1976) Immunological characterization of the subunit of the 100 A filaments from muscle cells. Proc Natl Acad Sci U S A 73: 4344-4348.
43. Lazarides E, Balzer DR Jr, (1978) Specificity of desmin to avian and mammalian muscle cells. Cell 14: 429-438.
44. Li Z, Mericskay M, Agbulut O, Butler-Browne G, Carlsson L, et al. (1997) Desmin is essential for the tensile strength and integrity of myofibrils but not for myogenic commitment, differentiation, and fusion of skeletal muscle. J Cell Biol 139: 129-144.
45. Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y, (1996) Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 134: 1255-1270.
46. Ervasti JM, (2003) Costameres: the Achilles' heel of Herculean muscle. J Biol Chem 278: 13591-13594.
47. O'Neill A, Williams MW, Resneck WG, Milner DJ, Capetanaki Y, et al. (2002) Sarcolemmal organization in skeletal muscle lacking desmin: evidence for cytokeratins associated with the membrane skeleton at costameres. Mol Biol Cell 13: 2347-2359.
48. Li Z, Colucci-Guyon E, Pincon-Raymond M, Mericskay M, Pournin S, et al. (1996) Cardiovascular lesions and skeletal myopathy in mice lacking desmin. Dev Biol 175: 362-366.
49. Wilding JR, Schneider JE, Sang AE, Davies KE, Neubauer S, et al. (2005) Dystrophin- and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J 19: 79-81.
50. Lewis C, Ohlendieck K, (2010) Proteomic profiling of naturally protected extraocular muscles from the dystrophin-deficient mdx mouse. Biochem Biophys Res Commun 396: 1024-1029.
51. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA, (2007) Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 21: 2195-2204.
52. Lovering RM, O'Neill A, Muriel JM, Prosser BL, Strong J, et al. (2011) Physiology, structure, and susceptibility to injury of skeletal muscle in mice lacking keratin 19-based and desmin-based intermediate filaments. Am J Physiol Cell Physiol 300: C803-813.
53. Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS, (2008) Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 16: 1539-1545.
54. Takemitsu M, Ishiura S, Koga R, Kamakura K, Arahata K, et al. (1991) Dystrophin-related protein in the fetal and denervated skeletal muscles of normal and mdx mice. Biochem Biophys Res Commun 180: 1179-1186.
55. Sewry CA, Nowak KJ, Ehmsen JT, Davies KE, (2005) A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours. Neuromuscul Disord 15: 779-785.
56. Li H, Capetanaki Y, (1994) An E box in the desmin promoter cooperates with the E box and MEF-2 sites of a distal enhancer to direct muscle-specific transcription. EMBO J 13: 3580-3589.
57. Weitzer G, Milner DJ, Kim JU, Bradley A, Capetanaki Y, (1995) Cytoskeletal control of myogenesis: a desmin null mutation blocks the myogenic pathway during embryonic stem cell differentiation. Dev Biol 172: 422-439.
58. Capetanaki Y, Milner DJ, Weitzer G, (1997) Desmin in muscle formation and maintenance: knockouts and consequences. Cell Struct Funct 22: 103-116.
59. Agbulut O, Li Z, Perie S, Ludosky MA, Paulin D, et al. (2001) Lack of desmin results in abortive muscle regeneration and modifications in synaptic structure. Cell Motil Cytoskeleton 49: 51-66.
60. Konieczny P, Fuchs P, Reipert S, Kunz WS, Zeold A, et al. (2008) Myofiber integrity depends on desmin network targeting to Z-disks and costameres via distinct plectin isoforms. J Cell Biol 181: 667-681.
61. Ohlendieck K, Campbell KP, (1991) Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol 115: 1685-1694.
62. Fong AP, Tapscott SJ, (2013) Skeletal muscle programming and re-programming. Curr Opin Genet Dev 23: 568-573.
63. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ, (2006) MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 175: 77-85.
64. Basu U, Lozynska O, Moorwood C, Patel G, Wilton SD, et al. (2011) Translational regulation of utrophin by miRNAs. PLoS One 6: e29376.
65. Gramolini AO, Jasmin BJ, (1999) Expression of the utrophin gene during myogenic differentiation. Nucleic Acids Res 27: 3603-3609.
66. Shah SB, Davis J, Weisleder N, Kostavassili I, McCulloch AD, et al. (2004) Structural and functional roles of desmin in mouse skeletal muscle during passive deformation. Biophys J 86: 2993-3008.
67. Marklund N, Bareyre FM, Royo NC, Thompson HJ, Mir AK, et al. (2007) Cognitive outcome following brain injury and treatment with an inhibitor of Nogo-A in association with an attenuated downregulation of hippocampal growth-associated protein-43 expression. J Neurosurg 107: 844-853.
68. Vergani L, Grattarola M, Nicolini C, (2004) Modifications of chromatin structure and gene expression following induced alterations of cellular shape. Int J Biochem Cell Biol 36: 1447-1461.
69. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE, (1997) Geometric control of cell life and death. Science 276: 1425-1428.
70. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, et al. (2004) Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 113: 357-369.
71. Favre B, Schneider Y, Lingasamy P, Bouameur JE, Begre N, et al. (2011) Plectin interacts with the rod domain of type III intermediate filament proteins desmin and vimentin. Eur J Cell Biol 90: 390-400.
72. Konieczny P, Wiche G, (2008) Muscular integrity-a matter of interlinking distinct structures via plectin. Adv Exp Med Biol 642: 165-175.
73. Gramolini AO, Belanger G, Thompson JM, Chakkalakal JV, Jasmin BJ, (2001) Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events. Am J Physiol Cell Physiol 281: C1300-1309.
74. Angus LM, Chakkalakal JV, Mejat A, Eibl JK, Belanger G, et al. (2005) Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. Am J Physiol Cell Physiol 289: C908-917.
75. Hollinger K, Gardan-Salmon D, Santana C, Rice D, Snella E, et al. (2013) Rescue of dystrophic skeletal muscle by PGC-1alpha involves restored expression of dystrophin-associated protein complex components and satellite cell signaling. Am J Physiol Regul Integr Comp Physiol 305: R13-23.
76. Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL, (2012) Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PLoS One 7: e30063.
77. Chakkalakal JV, Stocksley MA, Harrison MA, Angus LM, Deschenes-Furry J, et al. (2003) Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc Natl Acad Sci U S A 100: 7791-7796.
78. Chakkalakal JV, Harrison MA, Carbonetto S, Chin E, Michel RN, et al. (2004) Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum Mol Genet 13: 379-388.
79. St-Pierre SJ, Chakkalakal JV, Kolodziejczyk SM, Knudson JC, Jasmin BJ, et al. (2004) Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J 18: 1937-1939.
80. Stupka N, Schertzer JD, Bassel-Duby R, Olson EN, Lynch GS, (2007) Calcineurin-A alpha activation enhances the structure and function of regenerating muscles after myotoxic injury. Am J Physiol Regul Integr Comp Physiol 293: R686-694.
81. Michel RN, Chin ER, Chakkalakal JV, Eibl JK, Jasmin BJ, (2007) Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. Appl Physiol Nutr Metab 32: 921-929.
82. Ljubicic V, Miura P, Burt M, Boudreault L, Khogali S, et al. (2011) Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum Mol Genet 20: 3478-3493.
83. Miura P, Chakkalakal JV, Boudreault L, Belanger G, Hebert RL, et al. (2009) Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet 18: 4640-4649.
84. Miura P, Andrews M, Holcik M, Jasmin BJ, (2008) IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells. PLoS One 3: e2309.
85. Meyer GA, Lieber RL, (2012) Skeletal muscle fibrosis develops in response to desmin deletion. Am J Physiol Cell Physiol 302: C1609-1620.
86. Meyer GA, Schenk S, Lieber RL, (2013) Role of the cytoskeleton in muscle transcriptional responses to altered use. Physiol Genomics 45: 321-331.
87. Price MG, Lazarides E, (1983) Expression of intermediate filament-associated proteins paranemin and synemin in chicken development. J Cell Biol 97: 1860-1874.
88. Bellin RM, Sernett SW, Becker B, Ip W, Huiatt TW, et al. (1999) Molecular characteristics and interactions of the intermediate filament protein synemin. Interactions with alpha-actinin may anchor synemin-containing heterofilaments. J Biol Chem 274: 29493-29499.
89. Russell MA, Lund LM, Haber R, McKeegan K, Cianciola N, et al. (2006) The intermediate filament protein, synemin, is an AKAP in the heart. Arch Biochem Biophys 456: 204-215.
90. Ozawa T, (2010) Modulation of ryanodine receptor Ca2+ channels (Review). Mol Med Rep 3: 199-204.
91. Danila CI, Hamilton SL, (2004) Phosphorylation of ryanodine receptors. Biol Res 37: 521-525.
92. Fuller MD, Emrick MA, Sadilek M, Scheuer T, Catterall WA, (2010) Molecular mechanism of calcium channel regulation in the fight-or-flight response. Sci Signal 3: ra70.
93. Gramolini AO, Trivieri MG, Oudit GY, Kislinger T, Li W, et al. (2006) Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation. Proc Natl Acad Sci U S A 103: 2446-2451.
94. Peter AK, Marshall JL, Crosbie RH, (2008) Sarcospan reduces dystrophic pathology: stabilization of the utrophin-glycoprotein complex. J Cell Biol 183: 419-427.
95. Marshall JL, Holmberg J, Chou E, Ocampo AC, Oh J, et al. (2012) Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration. J Cell Biol 197: 1009-1027.
96. Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT, (2002) Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci U S A 99: 5616-5621.
97. Gauthier-Rouviere C, Bonet-Kerrache A, (2009) RhoA leads to up-regulation and relocalization of utrophin in muscle fibers. Biochem Biophys Res Commun 384: 322-328.
98. Challa AA, Stefanovic B, (2011) A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol Cell Biol 31: 3773-3789.
99. Moorwood C, Soni N, Patel G, Wilton SD, Khurana TS, (2013) A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation. J Biomol Screen 18: 400-406.
100. Chakkalakal JV, Miura P, Belanger G, Michel RN, Jasmin BJ, (2008) Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling. Nucleic Acids Res 36: 826-838.
101. Capetanaki Y, Bloch RJ, Kouloumenta A, Mavroidis M, Psarras S, (2007) Muscle intermediate filaments and their links to membranes and membranous organelles. Exp Cell Res 313: 2063-2076.
102. Li W, Zhang Q, Oiso N, Novak EK, Gautam R, et al. (2003) Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 35: 84-89.
103. Rafael JA, Tinsley JM, Potter AC, Deconinck AE, Davies KE, (1998) Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 19: 79-82.
104. Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis KA, Lowe DA, et al. (2009) Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med 6: e1000083.
105. Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, et al. (2006) Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20: 1724-1726.
106. Li D, Bareja A, Judge L, Yue Y, Lai Y, et al. (2010) Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J Cell Sci 123: 2008-2013.
107. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, et al. (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343: 180-182.
108. Albrecht DE, Froehner SC, (2002) Syntrophins and dystrobrevins: defining the dystrophin scaffold at synapses. Neurosignals 11: 123-129.
109. Adams ME, Mueller HA, Froehner SC, (2001) In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J Cell Biol 155: 113-122.
110. Shah SB, Love JM, O'Neill A, Lovering RM, Bloch RJ, (2012) Influences of desmin and keratin 19 on passive biomechanical properties of mouse skeletal muscle. J Biomed Biotechnol 2012: 704061.
111. Kornegay JN, Childers MK, Bogan DJ, Bogan JR, Nghiem P, et al. (2012) The paradox of muscle hypertrophy in muscular dystrophy. Phys Med Rehabil Clin N Am 23: 149-172, xii.
112. Banks GB, Combs AC, Chamberlain JS, (2010) Sequencing protocols to genotype mdx, mdx(4cv), and mdx(5cv) mice. Muscle Nerve 42: 268-270.
113. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12: 787-789.
114. Banks GB, Chamberlain JS, Froehner SC, (2009) Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci 40: 433-441.
115. Gregorevic P, Meznarich NA, Blankinship MJ, Crawford RW, Chamberlain JS, (2008) Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. Muscle Nerve 37: 104-106.
116. Banks GB, Gregorevic P, Allen JM, Finn EE, Chamberlain JS, (2007) Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Hum Mol Genet 16: 2105-2113.
117. Hanft LM, Rybakova IN, Patel JR, Rafael-Fortney JA, Ervasti JM, (2006) Cytoplasmic gamma-actin contributes to a compensatory remodeling response in dystrophin-deficient muscle. Proc Natl Acad Sci U S A 103: 5385-5390.
118. Gubern C, Hurtado O, Rodriguez R, Morales JR, Romera VG, et al. (2009) Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC Mol Biol 10: 57.